新辅助治疗在食管癌治疗中的应用

doi:10.3760/cma.j.cn371439-20190929-00011

摘要/Abstract

摘要：

新辅助治疗联合手术是一种非常具有医学前景的食管癌临床治疗策略,综合其有效性和安全性,新辅助放疗可作为重度食管癌、不可切除食管癌的治疗手段,新辅助化疗在腺癌中治疗价值更高,新辅助放化疗可作为鳞状细胞癌患者的推荐治疗方案。

Abstract:

Neoadjuvant therapy combined with surgery is a very promising clinical treatment strategy for esophageal cancer. Combined with its effectiveness and safety, neoadjuvant radiotherapy can be used as a treatment method for severe esophageal cancer and unresectable esophageal cancer. Neoadjuvant chemotherapy has a higher value in the treatment of adenocarcinoma. Neoadjuvant cheoradiotherapy can be used as the recommended treatment scheme for patients with squamous cancer.

Key words: Esophageal neoplasms, Neoplasms,squamous cell, Adenocarcinoma, Neoadjuvant therapy

卜茜, 黄俊星. 新辅助治疗在食管癌治疗中的应用[J]. 国际肿瘤学杂志, 2020, 47(4): 244-248.

Bu Qian, Huang Junxing. Application of neoadjuvant therapy in the treatment of esophageal cancer[J]. Journal of International Oncology, 2020, 47(4): 244-248.

参考文献 27

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.v68.6
[2]	Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[3]	汪楣, 谷铣之, 黄国俊 , 等. 食管癌术前放射治疗的前瞻性临床研究[J]. 中华放射肿瘤学杂志, 2001,10(3):168-171. DOI: 10.3760/j.issn:1004-4221.2001.03.007.
[4]	Thumallapally N, Meshref A, Mousa M , et al. Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis[J]. J Gastrointest Oncol, 2017,8(5):825-832. DOI: 10.21037/jgo.2017.06.19.
[5]	Chan KKW, Saluja R, Delos Santos K , et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis[J]. Int J Cancer, 2018,143(2):430-437. DOI: 10.1002/ijc.31312.
[6]	谭黎杰, 汪灏, 唐汉 . 局部进展期食管癌新辅助治疗的现状与展望[J]. 中华消化外科杂志, 2017,16(5):450-453. DOI: 10.3760/cma.j.issn.1673-9752.2017.05.003.
[7]	闫海霞, 符国胜 . 术前放疗对食管癌患者影响的临床分析[J]. 当代医学, 2011,17(16):21-22. DOI: 10.3969/j.issn.1009-4393.2011.16.014.
[8]	Zhu Y, Liu M, Yun X , et al. Meta-analysis for the therapeutic effect of neoadjuvant therapy in resectable esophageal cancer[J]. Pathol Oncol Res, 2017,23(3):657-663. DOI: 10.1007/s12253-016-0164-4.
[9]	Hara H, Tahara M, Daiko H , et al. Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma[J]. Cancer Sci, 2013,104(11):1455-1460. DOI: 10.1111/cas.12274.
[10]	Pasquali S, Yim G, Vohra RS , et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis[J]. Ann Surg, 2017,265(3):481-491. DOI: 10.1097/SLA.000000000000-1905.
[11]	Ma S, Yan T, Liu D , et al. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma[J]. Thoracic Cancer, 2018,9(2):310-315. DOI: 10.1111/1759-7714.12590.
[12]	Zheng Y, Li Y, Liu X , et al. Reevaluation of neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials over the past 20 years[J]. Medicine (Baltimore), 2015,94(27):e1102. DOI: 10.1097/MD.0000000000001102.
[13]	Tanaka K, Miyata H, Sugimura K , et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts[J]. Carcinogenesis, 2015,36(8):894-903. DOI: 10.1093/carcin/bgv067.
[14]	Yoshida N, Baba Y, Shigaki H , et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2016,21(6):1071-1078. DOI: 10.1007/s10147-016-0994-9.
[15]	van Hagen P, Hulshof MC, van Lanschot JJ , et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. New Engl J Med, 2012,366(22):2074-2084. DOI: 10.1056/NEJMoa1112088.
[16]	Shapiro J, van Lanschot JJB, Hulshof MCCM , et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/s1470-2045(15)00040-6.
[17]	Mantziari S, Gronnier C, Renaud F , et al. Survival benefit of neoadjuvant treatment in clinical T₃N₀M₀ esophageal cancer: results from a retrospective multicenter European study[J]. Ann Surg, 2017,266(5):805-813. DOI: 10.1097/SLA.000000000000-2402.
[18]	Yang H, Liu H, Chen Y , et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2097-2083. DOI: 10.1200/JCO.2018.79.1483.
[19]	刘施亮, 习勉, 杨雅迪 , 等. 局部晚期食管鳞癌新辅助放化疗联合手术治疗的临床疗效分析[J]. 中华放射肿瘤学杂志, 2015,24(3):232-236. DOI: 10.3760/cma.j.issn.1004-4221.2015.03.002. doi: 10.3760/cma.j.issn.1004-4221.2015.03.002
[20]	Hamai Y, Hihara J, Taomoto J , et al. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer[J]. Dis Esophagus, 2015,28(4):358-364. DOI: 10.1111/dote.12207.
[21]	Ychou M, Boige V, Pignon JP , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011,29(13):1715-1721. DOI: 10.1200/JCO.2010.33.0597.
[22]	Ronellenfitsch U, Schwarzbach M, Hofheinz R , et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer, 2013,49(15):3149-3158. DOI: 10.1016/j.ejca.2013.05.029. doi: 10.1016/j.ejca.2013.05.029
[23]	Alderson D, Cunningham D, Nankivell M , et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2017,18(9):1249-1260. DOI: 10.1016/s1470-2045(17)30447-3.
[24]	Kumagai K, Rouvelas I, Tsai JA , et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis[J]. Eur J Surg Oncol, 2015,41(3):282-294. DOI: 10.1016/j.ejso.2014.11.039.
[25]	Stahl M, Walz MK, Riera-Knorrenschild J , et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial[J]. Eur J Cancer, 2017,81:183-190. DOI: 10.1016/j.ejca.2017.04.027. doi: 10.1016/j.ejca.2017.04.027
[26]	Deng HY, Wang WP, Wang YC , et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg, 2017,51(3):421-431. DOI: 10.1093/ejcts/ezw315.
[27]	Bibby BA, Reynolds JV, Maher SG . MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma[J]. PLoS One, 2015,10(7):e0134180. DOI: 10.1371/journal.pone.0134180.